Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glepaglutide - Zealand Pharma

Drug Profile

Glepaglutide - Zealand Pharma

Alternative Names: ZP 1848

Latest Information Update: 26 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zealand Pharma
  • Class Anti-inflammatories; Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Short bowel syndrome
  • Discontinued Inflammatory bowel diseases

Most Recent Events

  • 22 Dec 2023 Preregistration for Short bowel syndrome (In the elderly, In adults) in USA (SC)
  • 14 Oct 2023 Efficacy data from a phase III EASE-SBS 1 trial in Short bowel syndrome presented at the 31st United European Gastroenterology Week (UEGW-2023)
  • 05 Sep 2023 Zealand Pharma completes a phase-III trial in Short bowel syndrome (In adults, In the elderly) in Denmark (SC) (EudraCT2020-005194-27) (NCT04991311)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top